The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial

Gjis F Snijders,1 Cornelia HM van den Ende,1 Piet LCM van Riel,2 Frank HJ van den Hoogen,1 Alfons A den Broeder; on behalf of NOAC study group

ABSTRACT

Objectives Evidence suggests that doxycycline might have disease-modifying properties in osteoarthritis. However, the clinically relevant question as to whether doxycycline also modifies symptoms in knee osteoarthritis is unanswered. The objective of this study was to investigate the effectiveness of doxycycline on pain and daily functioning in symptomatic knee osteoarthritis.

Methods A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic effectiveness of doxycycline twice a day 100 mg in knee osteoarthritis patients according to the clinical and radiological American College of Rheumatology classification criteria. The primary endpoint was the difference in the proportion of participants in both study groups achieving a clinical response defined by the OMERACT–OARSI set of responder criteria. Secondary endpoints included pain, stiffness, daily functioning, patient global assessment, quality of life, osteoarthritis-related medication and side effects.

Results 232 patients were randomly assigned. At study end, 31% of participants met the primary endpoint in both groups. Except for more adverse events in the doxycycline group, no differences were also found on the secondary endpoints.

Conclusions Doxycycline is not effective in reducing symptoms in knee osteoarthritis patients over a 24-week study period, but is associated with an increased risk of adverse events. Although a possible structure-modifying effect of doxycycline was previously suggested, this is not accompanied by symptom relief in the short and medium term.

Dutch Trial Register no NTR1111.

The search for a disease-modifying osteoarthritis drug (DMOAD) for osteoarthritis targeting both symptoms and structure has been intensified in recent years. Several studies investigating candidate DMOAD in clinical trials have been published, including dietary supplements, diacerein, strontium ranelate, bisphosphonates, biological agents, autologous conditioned serum, calcitonin and doxycycline.

However, up to now, no agent is known to be an irrefutable confirmed DMOAD as results of most studies remain largely ambiguous or difficult to interpret. For diacerein, risedronate, calcitonin and autologous conditioned serum the efficacy on symptoms have been demonstrated in randomised controlled trials, but these results have thus far not been confirmed in more than one study, except for diacerein. Effects on structural change have been shown for risedronate, diacerein and doxycycline, although these results have not been replicated successfully thus far. Whether doxycycline also modifies symptoms of osteoarthritis has not yet been established.

Doxycycline is a tetracycline class antibiotic agent. Besides being an antimicrobial agent, it is a metalloproteinase inhibitor and inhibits the collagenase that cleaves collagen type IX that is present in articular cartilage. Doxycycline has been studied in human osteoarthritis in one clinical trial, in which doxycycline was found to retard the progression of radiographic knee osteoarthritis. The original intent of this study was to assess the efficacy of doxycycline to retard progression and prevent the occurrence of radiographic knee osteoarthritis in overweight female patients with unilateral radiographic knee osteoarthritis. However, although the contralateral knee was radiographically normal in the conventional anterior–posterior (AP) view, in most cases there was evidence of osteoarthritis in the lateral, semiflexed AP and/or patellofemoral view. Therefore, de facto the effect of doxycycline on the progression of less extensive osteoarthritis in that joint was assessed. Although no effect on less extensive knee osteoarthritis was seen, radiographic progression was substantially slower in the knee with established osteoarthritis. No effect on pain was found, presumably due to low pain scores at enrolment. However, post-hoc analyses demonstrated a lower incidences of increased pain (>20% increase in pain score) in the index knee but not in the non-affected knee. Also, side effects were mild, and drop-out due to the possible side effects of doxycycline was rare (~8%) during the 30-month trial period.

Although a proof of principle of DMOAD properties of doxycycline has thus been demonstrated, the clinically relevant question as to whether doxycycline also reduces pain and improves daily functioning in symptomatic knee osteoarthritis has not been answered.

To explore the effects of doxycycline on reducing symptoms in knee osteoarthritis, a 24-week triple-blinded, randomised, placebo controlled trial was conducted to evaluate the effect of doxycycline on pain and daily functioning in well-established knee osteoarthritis.

METHODS

Study design
This triple-blinded, randomised, placebo controlled trial was performed as a mono-centre study in the Sint Maartenskliniek, Nijmegen, The Netherlands.
The local Medical Research Ethics Committee, region Arnhem/Nijmegen, The Netherlands, and the national Central Committee on Research involving Human Subjects (CCMO) approved the study. Moreover, the study was registered at EUDRACT and in the Dutch Trial Register (www.trialregister.nl; trial number: NTR1111). All participants gave their informed consent.

Participants

Patients were eligible for inclusion if they met the following criteria: fulfilment of the clinical and radiological American College of Rheumatology classification criteria for knee osteoarthritis in the index knee (defined as the knee causing most complaints during the screening visit), Kellgren and Lawrence (K&L) score 2 or 3, knee injury and osteoarthritis outcome score-derived Western Ontario McMaster Universities (WOMAC) score pain subscale (see details below) of greater than 20/100 and the ability to read and communicate well in Dutch. Exclusion criteria were: inflammatory rheumatic diseases or deposition diseases possibly leading to inflammatory arthritis or secondary osteoarthritis, extensive orthopaedic abnormalities (eg, major malalignment (>5°)), co-morbidity exceeding complaints of limitations of the knee, cognitive or sensomotor problems interfering with the use of questionnaires or intake of study medication, planned other major interventions within 24 weeks (including lower limb surgery and intensive multidisciplinary approaches), hip prosthesis in situ on the side of the symptomatic knee, contraindications for doxycycline use, such as allergy for tetracyclines and previous possible adequate treatment with doxycycline (>100 mg/day for >6 weeks for osteoarthritis), recent intra-articular hyaluronic acid/corticosteroid application or arthroscopy (<3 months) or open surgical procedures (<1 year) in the index knee.

Participants were allowed to use analgesics during the study period, but they were asked to stop these agents during the last 48 h and/or four times the drugs half-life before the study visits at the outpatient clinic (baseline, weeks 12 and 24). Opioids other than tramadol (up to 150 mg/day) were not allowed.

Participants were recruited from the rheumatology and orthopaedics outpatient clinics and from advertisements in local newspapers.

Setting

All visits and collection of data took place at the rheumatology outpatient clinic of the Sint Maartenskliniek, Nijmegen, The Netherlands, a hospital specialising in rheumatology, orthopaedics and rehabilitation.

Randomisation and intervention

Eligible patients were randomly assigned (allocation ratio 1:1) to receive either 100 mg of oral doxycycline monohydrate or placebo twice a day (one in the morning and one in the evening) for 24 weeks. The allocation was blinded for patient and study physician (GFS) using placebo medication capsules, blue and white, with the same appearance as verum. Participants who violated the study protocol were encouraged to adhere to study visits to limit loss to follow-up.

An independent pharmacist used a computer-generated, blinded randomisation list to assign patients randomly to doxycycline or placebo. Allocation data were stored at the hospital pharmacy in sealed envelopes that could be opened in the case of medical need. To increase balance in possible confounders, allocation was stratified for intensity of pain (moderate vs severe, ie, <60 vs ≥60 on the WOMAC pain subscale, respectively) at the screening visit using stratified block randomisation. Assignment of patients to the right stratum of the random assignment list was performed by the study physician (GFS) who was blinded to therapy.

Assessments

Visits were planned at screening (week -2), baseline, weeks 12 and 24 at the outpatient clinic and in weeks 6 and 18 by telephone. The following data were collected:

- Baseline characteristics: demographics, duration of complaints, previous osteoarthritis-related treatments, concomitant medication.
- Radiographs (at screening): bilateral (posterior–anteri fixation and lateral) knee radiographs were performed and graded using the K&L grading scale by the study physician (GFS).
- Questionnaires (at screening, baseline, week 12 and week 24): to estimate knee osteoarthritis-related symptoms patients were asked to fill out the Dutch version of the knee injury and osteoarthritis outcome score (Likert scale version) questionnaire. This questionnaire includes the WOMAC score in its complete and original format (with permission, http://www.koos.nu). WOMAC pain, stiffness and function subscales were presented as normalised scores (0–100, where 0 equals no symptoms). To assess quality of life, the short form 36 (SF-36) questionnaire was completed by all participants. The SF-36 consists of eight subscales with a score range of 0–100, where 100 represents the best possible health situation. The physical component summary (PCS) and mental component summary (MCS) scores were calculated as weighted means of the four physical and four mental subscale scores, respectively (higher scores indicate better health situation).
- Patient global assessment: visual analogue scale–patient global assessment (VAS–PGA), 0–100, where 0 equals no symptoms (at screening, baseline, week 12 and week 24).
- (Changes in) osteoarthritis related medication use (during all visits).
- Adverse events: during all follow-up visits patients were asked if they experienced any possible adverse events, which were graded for severity. Any adverse event resulting in death, hospitalisation, prolongation of hospitalisation, or development of a life-threatening or debilitating condition was categorised as a serious adverse event (SAE). Routine laboratory testing (baseline and week 24) included liver and renal function in addition to blood cell counts and vitamin B12 (the latter only at week 24).
- Therapy adherence: pill counts (weeks 12 and 24). Adherence to therapy was defined as the use of 80% or more of the total number of study capsules.

Outcome

The primary endpoint was the difference in the proportion of participants in both study groups achieving a clinical response at week 24 defined by the OMERACT–OARSI set of responder criteria, based on the WOMAC pain and function subscale scores and VAS–PGA. The OMERACT–OARSI criteria are defined as: (1) improvement in WOMAC pain (0–100) or WOMAC function (0–100) of 50% or greater with an absolute change of 20 or greater; or (2) improvement of 20% or greater with an absolute change of 10 or greater in at least two of the following measures: WOMAC pain, WOMAC function and VAS–PGA. Incomplete questionnaires at baseline...
were replaced by data from the screening visit (t=−2 weeks) if possible. In addition, incomplete questionnaires at study end (week 24) were replaced by data from the 12-week visit in participants who were still taking study medication at the end of the study (week 24). Participants who ceased study medication prematurely due to adverse events and were lost to follow-up were classified as non-responders. This analysis was performed in all subjects who underwent randomisation but also preplanned in subgroups with and without severe pain (intention-to-treat analysis).

Secondary endpoints included differences between the two study groups at weeks 12 and 24 in (change in) the WOMAC subscales, VAS–PGA, PCS and MCS subscales of the SF-36, nature and frequency of adverse events and the (change in) use of osteoarthritis-related medication at study end.

Sample size calculation
A difference of 20% response between the placebo and doxycycline group (number needed to treat 5) was considered to be clinically relevant. An OMERACT–OARSI response at 24 weeks in the placebo group of 40% was anticipated. Together with a requested power of 80%, a two-sided significance level of 0.05, an allocation ratio of 1:1 and an expected drop-out at week 24 of 15%, 115 patients were required per treatment arm.

Statistical analysis
Statistical analyses were performed using STATA/IC 10.1 for Windows. Descriptive statistics were provided by using mean (SD), median (25th–75th percentiles) or frequencies/percentages depending on distribution of the data. All analyses were performed blinded for treatment allocation.

Analysis of the primary endpoint was carried out using the intention-to-treat principle and was assessed using Fisher’s exact test. Change scores were calculated by subtracting the baseline scores from the scores at weeks 12 and 24, respectively. Differences between both study groups in change scores of baseline scores from the scores at weeks 12 and 24, respectively (p=1.0).

RESULTS
Between April 2008 and April 2010 232 of the 305 patients screened were enrolled and randomly assigned in this study (figure 1). Subjects in the doxycycline group reported slightly higher scores on the WOMAC subscales and concomitant use of analgesics compared with the placebo group. With respect to other possible confounding variables such as demographic variables, body mass index and K&L grade both study groups were comparable at baseline. Thirty-seven patients had severe pain (table 1).

Among the 232 subjects who were randomly assigned, 204 (88%) completed the trial per protocol. Significantly more participants in the doxycycline group compared with the placebo group discontinued the study medication prematurely (21 vs seven, p=0.001). Twelve participants were lost to follow-up (seven doxycycline vs five placebo group). Adherence to treatment was satisfactory (ie, ≥80% study capsules taken) in 88% of subjects who were still taking study medication at the final study visit (week 24) and was comparable between both study groups: 80% versus 80% in the doxycycline and placebo groups, respectively (p=1.0).

Figure 1. Study flow diagram
Primary outcome measure
A total of 72 out of 232 (31%) participants met the OMERACT–OARSI criteria for treatment response at the final study visit (week 24). In the doxycycline and placebo group, 31/116 (27%) and 41/116 (35%) met responder criteria at study end, respectively (p=0.2). In participants with severe pain at week 24, nine responders were identified (two of 19 in the doxycycline group vs seven of 18 in the placebo group). Again, no significant difference in the proportion of responders was identified between the doxycycline and placebo groups (p=0.06).

Secondary outcome measures
In the total study population, a significant improvement of symptoms was observed at week 24. Scores on the WOMAC subscales pain, stiffness and function, and VAS–PGA decreased from 49 to 41 (n=218), 56 to 50 (n=215), 49 to 42 (n=210) and 52 to 44 (n=200), respectively (all p<0.001). Regarding quality of life, PCS improved from 56 to 38 (p<0.0001), whereas MCS showed no change (53 vs 54, n=213, p=0.5). However, no differences between the two study groups were found in any measures (table 2).

Concomitant use of osteoarthritis-related medication
Of the 204 participants who were still taking study medication at the study end, 153 had unchanged, 23 had increased and 28 had decreased their osteoarthritis-related medication use at week 24. For the doxycycline and placebo groups these numbers were 68, 12, 15 and 85, 11, 13, respectively, and showed no significant difference between these groups (p<0.09).

Safety
During the study, 56% of the participants reported at least one adverse event. Of the 28 subjects who prematurely ceased study medication, 24 did so because of adverse events. Compared with the placebo group, significantly more participants who were

Table 1 Baseline characteristics of patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total study population (n=232)</th>
<th>Doxycycline (n=116)</th>
<th>Placebo (n=116)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>154 (66)</td>
<td>79 (68)</td>
<td>75 (65)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>59 (9)</td>
<td>59 (9)</td>
<td>59 (10)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>30 (5)</td>
<td>30 (6)</td>
<td>30 (5)</td>
</tr>
<tr>
<td>Duration of knee complaints (years), median (p25–75)</td>
<td>6 (3–15)</td>
<td>6 (3–14)</td>
<td>6 (3–15)</td>
</tr>
<tr>
<td>K&amp;L score = 2, number (%)</td>
<td>151 (65)</td>
<td>78 (66)</td>
<td>73 (65)</td>
</tr>
<tr>
<td>K&amp;L score = 3, number (%)</td>
<td>81 (35)</td>
<td>40 (34)</td>
<td>41 (35)</td>
</tr>
<tr>
<td>WOMAC score, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>49 (18)</td>
<td>52 (19)</td>
<td>46 (17)</td>
</tr>
<tr>
<td>Function</td>
<td>49 (18)</td>
<td>52 (18)</td>
<td>47 (17)</td>
</tr>
<tr>
<td>Stiffness</td>
<td>56 (21)</td>
<td>58 (22)</td>
<td>54 (19)</td>
</tr>
<tr>
<td>Severe pain, n (%)*</td>
<td>37 (16)</td>
<td>19 (16)</td>
<td>18 (16)</td>
</tr>
<tr>
<td>VAS–PGA, mean (SD)</td>
<td>52 (25)</td>
<td>52 (25)</td>
<td>53 (26)</td>
</tr>
<tr>
<td>Pain medication use, number (%)†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol</td>
<td>81 (35)</td>
<td>50 (43)</td>
<td>31 (27)</td>
</tr>
<tr>
<td>NSAID</td>
<td>95 (41)</td>
<td>51 (44)</td>
<td>44 (38)</td>
</tr>
<tr>
<td>Tramadol</td>
<td>12 (5)</td>
<td>4 (3)</td>
<td>9 (7)</td>
</tr>
<tr>
<td>None</td>
<td>85 (37)</td>
<td>34 (29)</td>
<td>51 (44)</td>
</tr>
</tbody>
</table>

*WOMAC pain subscale ≥80/100.
†Including on-demand use.
BMI, body mass index; K&L score, Kellgren–Lawrence grading scale; NSAID, non-steroidal anti-inflammatory drug; VAS–PGA, visual analogue scale–patient global assessment; WOMAC Western Ontario McMaster Universities score.

Table 2 Secondary outcomes: improvements and differences between study groups

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Doxycycline</th>
<th>Placebo</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOMAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>52 (19)</td>
<td>46 (17)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline</td>
<td>-8 (-4 to -11)</td>
<td>-7 (-4 to -11)</td>
<td>0 (-5 to 5)</td>
</tr>
<tr>
<td>∆ Week 24, baseline</td>
<td>-8 (-5 to -12)</td>
<td>-8 (-3 to -12)</td>
<td>0 (-6 to 5)</td>
</tr>
<tr>
<td>WOMAC stiffness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>58 (22)</td>
<td>54 (19)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline</td>
<td>-7 (-3 to -11)</td>
<td>-9 (-5 to -13)</td>
<td>2 (-4 to 7)</td>
</tr>
<tr>
<td>∆ Week 24, baseline</td>
<td>-5 (-1 to -8)</td>
<td>-5 (-3 to -12)</td>
<td>3 (-3 to 8)</td>
</tr>
<tr>
<td>WOMAC function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>52 (18)</td>
<td>47 (17)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline</td>
<td>-7 (-4 to -10)</td>
<td>-7 (-3 to -10)</td>
<td>1 (-5 to 4)</td>
</tr>
<tr>
<td>∆ Week 24, baseline</td>
<td>-8 (-4 to -11)</td>
<td>-7 (-3 to -10)</td>
<td>-1 (-6 to 4)</td>
</tr>
<tr>
<td>VAS–PGA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>52 (25)</td>
<td>53 (26)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline</td>
<td>-7 (-1 to -13)</td>
<td>-9 (-3 to -15)</td>
<td>1 (-7 to 10)</td>
</tr>
<tr>
<td>∆ Week 24, baseline</td>
<td>-7 (-1 to -13)</td>
<td>-10 (-3 to -17)</td>
<td>3 (-6 to 12)</td>
</tr>
<tr>
<td>PCS (possible range 4–71)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>36 (8)</td>
<td>36 (7)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline†</td>
<td>2 (0 to 3)</td>
<td>3 (1 to 4)</td>
<td>-1 (-3 to 1)</td>
</tr>
<tr>
<td>∆ Week 24, baseline†</td>
<td>2 (1 to 3)</td>
<td>2 (1 to 4)</td>
<td>0 (-2 to 3)</td>
</tr>
<tr>
<td>MCS (possible range 2–74)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (SD)</td>
<td>52 (11)</td>
<td>54 (11)</td>
<td></td>
</tr>
<tr>
<td>∆ Week 12, baseline†</td>
<td>1 (-1 to 2)</td>
<td>1 (-3 to 1)</td>
<td>2 (0 to 4)</td>
</tr>
<tr>
<td>∆ Week 24, baseline†</td>
<td>1 (-1 to 2)</td>
<td>0 (-1 to 2)</td>
<td>0 (-2 to 3)</td>
</tr>
</tbody>
</table>

Negative signs indicate improvement within groups (unless stated otherwise) or improvement in favour of doxycycline (in case of differences in change between groups). Scores are normalised (0–100; 0 = no symptoms) unless stated otherwise.
*Norm-based scores, higher scores indicate better health, individual scores in the 45–55 range indicate average health.
†Negative signs indicate deterioration within groups or improvement in favour of placebo (in case of differences in change between groups).
MCS, mental component score; PCS, physical component score; VAS–PGA, visual analogue scale–patient global assessment; WOMAC Western Ontario McMaster Universities score.
taking doxycycline ceased treatment because of side effects (19 vs five, p<0.01). Adverse events in both treatment groups reported by more than two subjects are shown in table 3.

The only adverse event that occurred significantly more often in one of the treatment groups was sun sensitivity. The cumulative incidence of upper respiratory tract infection was, however, somewhat lower in doxycycline-treated patients, although this did not reach significance. The development of laboratory abnormalities was rare and did not significantly differ between the treatment groups. In seven subjects (five doxycycline vs two placebo group) low–normal vitamin B12 levels were measured at the end of the study (p=0.3). A total of five SAE occurred during the trial: one traumatic patella fracture (placebo group); two myocardial infarctions (both doxycycline group); one total knee replacement (doxycycline group) and one arthroscopic meniscectomy (placebo group). None of the SAE were likely to have been attributable to doxycycline, therefore no suspected unexpected serious adverse reactions occurred during the trial.

Sensitivity analyses

Analysis regarding the proportion of responders in subjects who completed the trial per protocol yielded the same results as the primary analysis. Also, an analysis of (non-)response in adherent participants resulted in similar findings.

DISCUSSION

The findings of the present study indicate that doxycycline is not effective in reducing symptoms in knee osteoarthritis patients over a 24-week study period, but is associated with an increased risk of adverse events. Although previously a possible structure-modifying effect of doxycycline was suggested, this is not accompanied by symptom relief in the short and medium term. Because of the unfavourable risk–benefit ratio, doxycycline should not be used in the management of knee osteoarthritis.

The lack of effect seen in this study is not caused by insufficient adherence to the medication. Although pill counts showed that approximately 20% of the patients did not reach the target of taking 80% or more of the study medication, subanalysis in adherent participants yielded the same findings. Although varus malalignment may have negated the symptom-modifying effect of doxycycline, as reported for the structure-modifying effects of doxycycline, this seems very unlikely as major malalignment was one of the exclusion criteria.

Generalisability seems to be fair as the study group is comparable with other cohorts of knee osteoarthritis consisting mainly of middle-aged obese women. In this study a relatively low frequency of subjects experienced severe knee pain (16%). This is in contrast to other more symptomatic knee osteoarthritis cohort studies, like for example the secondary care CONTROL–PRO cohort, in which 54% of knee osteoarthritis patients experienced severe pain. However, stratified analyses in patients with severe pain did not show any trend for a symptom-reducing effect of doxycycline. Also, results of our study possibly cannot be extrapolated to knee osteoarthritis patients with low or high radiographic K&L scores (ie, ≤1 or >3). It could be possible that we included participants with slightly less extensive radiographic osteoarthritis compared with other studies, because radiographs obtained in the flexion view may have a higher sensitivity for osteoarthritis-related radiographic changes compared with conventional AP views. However, this does not challenge the validity of the present study as it does not compromise the external validity, because in both K&L groups a lack of response was observed indicating absence of effect modification.

To our knowledge, up to now no other studies have evaluated the effects of doxycycline on symptoms caused by osteoarthritis. As mentioned earlier, the only study of doxycycline in human knee osteoarthritis indicated that this agent retards radiographic progression of knee osteoarthritis, although the primary goal of the study—reduction of progression of less extensive knee osteoarthritis, was not met. A trend to pain reduction was also seen, possibly reflecting the anti-inflammatory effect of tetracyclines as studied for minocycline in rheumatoid arthritis.

Although doxycycline (as a metalloproteinase inhibitor) does not seem to be a symptom modifier in the short and medium term in knee osteoarthritis patients with moderate pain, this agent could still have potential structure-modifying effects. However, the use of doxycycline for a longer period has some drawbacks regarding side effects (mainly sun sensitivity) and possibly the development of antimicrobial resistance. Therefore, efforts have been made to develop synthetic metalloproteinase inhibitors although until now without a favourable risk–benefit ratio.

Future research should give insight into the structure-modifying properties of the inhibition of metalloproteinases

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Total study population (n=232), n (%)</th>
<th>Doxycycline (n=116), n (%)</th>
<th>Placebo (n=116), n (%)</th>
<th>p Value</th>
<th>Doxycycline ( \frac{\text{Led to temporarily discontinuation, n}^1}{\text{Led to permanent discontinuation, n}} )</th>
<th>Placebo ( \frac{\text{Led to temporarily discontinuation, n}}{\text{Led to permanent discontinuation, n}} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun sensitivity</td>
<td>38(16)</td>
<td>35(30)</td>
<td>3(3)</td>
<td>&lt;0.001</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>25(11)</td>
<td>15(13)</td>
<td>10(9)</td>
<td>0.40</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>16(7)</td>
<td>6(5)</td>
<td>10(9)</td>
<td>0.44</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Erythema</td>
<td>12(5)</td>
<td>8(7)</td>
<td>4(3)</td>
<td>0.38</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Nausea</td>
<td>10(4)</td>
<td>5(4)</td>
<td>5(4)</td>
<td>1.0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>9(4)</td>
<td>2(2)</td>
<td>7(6)</td>
<td>0.17</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia/myalgia</td>
<td>8(3)</td>
<td>4(3)</td>
<td>4(3)</td>
<td>1.0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Headache</td>
<td>7(3)</td>
<td>4(3)</td>
<td>3(3)</td>
<td>1.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oedema</td>
<td>6(3)</td>
<td>3(3)</td>
<td>3(3)</td>
<td>1.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>6(3)</td>
<td>4(3)</td>
<td>2(2)</td>
<td>0.68</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mycosis</td>
<td>5(2)</td>
<td>4(3)</td>
<td>1(1)</td>
<td>0.37</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Other</td>
<td>26(11)</td>
<td>10(9)</td>
<td>16(14)</td>
<td>0.30</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

*Subjects could have reported more than one adverse event.

1Subjects could have ceased treatment because of more than one adverse event.
in human osteoarthritis. Regarding symptom modifying in osteoarthritis, improvement of the strategies of existing treatment modalities\(^5\) or the development of new classes of analgesics\(^6\) will probably result in better outcomes in patients with symptomatic osteoarthritis.

In conclusion, the present study showed that twice daily doxycycline for 24 weeks did not have any effect on symptoms in knee osteoarthritis patients, compared with placebo. Therefore, doxycycline should not be applied as a symptom modifier in knee osteoarthritis.

Acknowledgements The authors thank Dr BJF van den Berst for study medication supply, FW Snijders and NWO Eikenboom for data entry and management, and VHNP Straten and MA Arts-Sanders for patient screening.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the local Medical Research Ethics Committee, region Amsterdam-Nijmegen, The Netherlands, and the national Central Committee on Research involving Human Subjects (CCMO).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


http://ard.bmj.com/ Downloaded from
The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial

Gijs F Snijders, Cornelia HM van den Ende, Piet LCM van Riel, Frank HJ van den Hoogen and Alfons A den Broeder

Ann Rheum Dis 2011 70: 1191-1196 originally published online May 8, 2011
doi: 10.1136/ard.2010.147967

Updated information and services can be found at:
http://ard.bmj.com/content/70/7/1191

These include:

References
This article cites 37 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/70/7/1191#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (161)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Osteoarthritis (931)
Pain (neurology) (683)
Epidemiology (1376)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/